NCT05640778 2024-01-31
Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
Clinical Trials
14 trialsNCT05801705 2023-05-18
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Unknown
NCT02914158 2023-01-17
ASPAIT
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Unknown
NCT05000736 2022-04-29
CAPACITY
ChineseAMS
Unknown
NCT04088110 2019-09-12
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Fuzhou General Hospital
Phase 2 Unknown
NCT04012918 2019-07-09
CONCEPT
Ain Shams University
Phase 2 Unknown
NCT03910712 2019-04-10
Pyrotinib
Peking Union Medical College Hospital
Phase 2 Unknown
NCT02769104 2018-01-09
ACCN
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT02910050 2017-12-22
BETTER
Sun Yat-sen University
Phase 2 Unknown
NCT02394496 2016-06-15
OVER
Consorzio Oncotech
Phase 3 Unknown
NCT01924078 2013-08-16
Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer
Fudan University
Phase 2 Unknown
NCT00629278 2013-08-07
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT01654367 2012-07-31
esozao
Tianjin Medical University
Phase 2/3 Unknown
NCT01311037 2011-12-13
The Combination of GnRh Analogue and Aromatase Inhibitor in Receptor Positive Premenopausal Women With Advanced Breast Cancer
King Faisal Specialist Hospital & Research Center
Unknown